| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Silo Pharma reports stability data for intranasal drug SPC-15 | 1 | Investing.com | ||
| Di | Silo Pharma, Inc.: Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial | 2 | GlobeNewswire (USA) | ||
| Do | Silo Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| SILO PHARMA Aktie jetzt für 0€ handeln | |||||
| Do | Silo Pharma regains Nasdaq bid price compliance | 1 | Seeking Alpha | ||
| Do | Silo Pharma, Inc.: Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement | 197 | GlobeNewswire (Europe) | SARASOTA, FLA., June 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) ("Silo" or "the Company"), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery... ► Artikel lesen | |
| 01.06. | Silo Pharma kündigt Aktienzusammenlegung im Verhältnis 1:15 an | - | Investing.com Deutsch | ||
| 01.06. | Silo Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.05. | Silo Pharma, Inc.: Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury | 442 | GlobeNewswire (Europe) | New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines Silo Pharma targets unmet need in a drug market with no FDA-approved... ► Artikel lesen | |
| 29.04. | Silo Pharma, Inc.: Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD | 176 | GlobeNewswire (Europe) | Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment SARASOTA, Fla, April 29, 2026 (GLOBE NEWSWIRE) -- Silo Pharma... ► Artikel lesen | |
| 22.04. | Silo Pharma launches AI subsidiary, advances PTSD drug program | 3 | Investing.com | ||
| 22.04. | Silo Pharma, Inc.: Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents | 1.070 | GlobeNewswire (Europe) | Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1 SARASOTA, FL, April 22, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:... ► Artikel lesen | |
| 20.04. | Silo Pharma highlights PTSD treatment program amid policy shift | 2 | Investing.com | ||
| 20.04. | Silo Pharma highlights PTSD drug program amid policy shift | 1 | Investing.com | ||
| 20.04. | Silo Pharma rückt PTSD-Programm nach politischem Kurswechsel in den Fokus | 1 | Investing.com Deutsch | ||
| 20.04. | Silo Pharma, Inc.: Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics | 637 | GlobeNewswire (Europe) | SPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health Therapies SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO), a developmental-stage... ► Artikel lesen | |
| 07.04. | Silo Pharma-Aktie schießt nach europäischer Patent-Zusage in die Höhe | 1 | Investing.com Deutsch | ||
| 07.04. | Why Silo Pharma Shares Are Trading Higher By Around 52%; Here Are 20 Stocks Moving Premarket | 2 | Benzinga.com | ||
| 07.04. | Stock Market Today: Dow, S&P 500 Futures Rise Ahead Of Trump's 'Power Plant Day' Deadline-UnitedHealth, Silo Pharma, Phillips 66 In Focus | 5 | Benzinga.com | ||
| 07.04. | Silo Pharma (SILO) Stock Soars 47% After European Patent Win: What You Should Know | 1 | Benzinga.com | ||
| 06.04. | Silo Pharma receives European patent approval for stress prevention therapy | 1 | Investing.com |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,50 | -0,25 % | BioNTech-Aktie: Ist das Unternehmen noch zu retten? | Die Geschichte von BioNTech ist eine der größten Erfolgsgeschichten der deutschen Wirtschaft. Aus einem Mainzer Forschungsunternehmen wurde innerhalb weniger Jahre ein globaler Pharmakonzern, dessen... ► Artikel lesen | |
| VALNEVA | 2,329 | +0,09 % | Was Insider bei Valneva heute bereits wissen: 0,0% Plus und das könnte erst der Anfang sein - Was erfahrene Trader jetzt tun | ||
| AMGEN | 305,70 | +0,30 % | EQS-News: Amgen: Europäische Kommission erteilt Zulassung für Imdylltra von Amgen für die Behandlung von kleinzelligem Lungenkrebs im fortgeschrittenen Stadium | EQS-News: Amgen
/ Schlagwort(e): Sonstiges/Sonstiges
EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM... ► Artikel lesen | |
| NOVAVAX | 7,960 | +0,76 % | Novavax-Aktionäre billigen auf Hauptversammlung wichtige Anträge | ||
| BIOGEN | 175,20 | +1,12 % | Biogen Inc.: Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. | Acquisition adds multiple immunology assets to Biogen's portfolio, including a lead asset poised to enter Phase 1 developmentCAMBRIDGE, Mass. and SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Biogen... ► Artikel lesen | |
| ILLUMINA | 144,92 | +0,01 % | IQM Quantum Computers: IQM ernennt Craig Ciesla, ehemaligen Illumina VP, zum CTO und Inés de Vega wird Chief Scientist | Ciesla ist eine erfahrene Tech-Führungskraft mit mehr als 25 Jahren Erfahrung mit der Entwicklung von Produkten von Startups bis Fortune 500-Unternehmen.
De Vega hat mehr als 20 Jahre Erfahrung... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,345 | -0,19 % | Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year | ||
| VIVOSIM LABS | 1,120 | -0,88 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Announces Asset Sale Agreements; Commences Chapter 11 Proceedings | INDIANAPOLIS (dpa-AFX) - Sangamo Therapeutics has entered into two separate asset sale agreements, one with Eli Lilly and Company (LLY) for Sangamos capsid delivery platform, zinc finger platform... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,950 | +1,14 % | Viking Therapeutics begins phase 1 trial of weight loss drug | ||
| INTELLIA THERAPEUTICS | 13,240 | -1,19 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| TEMPUS AI | 42,770 | +0,15 % | Should You Retain Tempus AI Stock In Your Portfolio Now? | ||
| EDITAS MEDICINE | 2,450 | +1,24 % | Editas Medicine, Inc. - 8-K, Current Report | ||
| VIVORYON THERAPEUTICS | 1,060 | +2,42 % | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update
Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,202 | +0,29 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen |